Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
turbans are worn by sikhs, of which they are less than 2% of india’s population … for how long will lse allow ****** comments to be made against an individual! deleting the post isn’t enough. ban him!
It’s a government delay from the way I read it
Https://www.gov.uk/government/news/new-measures-to-support-sustainable-aviation-fuel-industry
Rick - Remember they dont want to be a producer, the idea is they provide a cookie cutter template for companies to develop these plants on their own. Their business model is reactor licensing.
No worries Gary, worth keeping an eye out for these industry events as they often give a small insight into whats going on. Most valuable slide imo was the timelines, looks like funding isnt due for a while.
GLA
Fwiw Hulver I put this questions to Vlad and Peter over email. Even offered the recording to them where Vlad stated exactly what you have written below. Neither responded. Chased recently, still nothing. I would suggest those who seem to have a more open relationship to ask them to provide clarification at the earliest opportunity.
Link to the tweet, Vlad has also liked the post.
Roll on CBR update! We kind of knew it was coming but to start seeing the PR machine warm up is more than welcome, my gut tells me it is positive !
https://x.com/davidburton1971/status/1691809427928564062?s=46&t=ywyydXEp4mIT7KLnbt9ZqA
Traders may want to have some fun with this as we await news. Looking at the thin volumes I certainly wouldnt want to be selling what you cant buy back!
Vlad LinkedIn Repost - is this the AI question answered !?
Pretty epic news! Recursion screened 36 billion molecules from Enamine Ltd. against 15,000 human proteins containing more than 80,000 potential binding pockets. In total, this screen digitally evaluated more than 2.8 quadrillion small molecule-target pairs.
First of all, I am proud of my colleagues at Enamine, who created REAL compounds, and made them into one-of-a-kind resources for virtual screening. This chemical platform has a history that dates back more than a decade of validating chemical reactions and synthesizing innovative and robust reagents (building blocks).
I also sincerely congratulate the team at Recursion, an apparent leader in the emerging TechBio space. They've gone through the massive Enamine REAL Space chemical library and matched up to 36 billion (!) compounds with their protein partners. They did this with the help of their in-house supercomputer, BioHive-1, and NVIDIA DGX Cloud and they used a cool deep learning-based platform called MatchMaker, originally developed by Cyclica. The latter was acquired by Recursion several months ago.
Folks at Recursion generated this massive new data layer of predicted interactions in less than 90 days after closing the acquisition of Cyclica and in under 30 days since initiating the collaboration with NVIDIA.
Link to full press release in the comments below.
#drugdiscovery #deeplearning #biopharmatrend
Kicking myself I didn’t ask about the AI element at the AGM!
Extract from the annual report. (Mainly covering CBR)
“The Company's technology utilises synthetic biology and artificial intelligence approaches to advance medicine to protect society from future pandemics that may challenge the global economy, health, and national defence. When fully developed, we would be able to create front-line treatments that may prevent the development of the next pandemic. Moreover, these new therapeutic tools can be used to protect against bio-terrorism, potentially rendering a universe of viral bio-weapons ineffective.
We continue to believe that this platform has the capacity to be extremely valuable.”
Incredible to see them use it across different product candidates. Must be some bit of kit !
Great research MR I, a lot of food for thought within there. I’m not from a science background myself but those timeframes seem to align with Vlads comments about it being a quick fix, I guess we may be in the midst of PQ runs and not even know it. The last PQ runs were put to the market via Reg RNA so that suggests optionality from the company as to whether or not they inform us. Hopefully we are very close to a nice “resubmitted” or even better “approved” surprise !
@SocialistB - thanks for getting back to me. Interesting angle with regard to people being away. Hadn’t considered that but would certainly mean thinner vols. Hopefully all studies are progressing well!
Hi all, just a quick one. I recall Dr VS stating that in vivo studies are yet to take place. This was at the most recent AGM. If I remember correctly it is the in vitro studies that are on going (progressing well - in his words) and once they are complete the decision will be made whether to go in vivo. Did anyone else have a different understanding ? Thanks
Thanks HK, my thinking was in relation to the PQ runs we saw earlier in the year. Appreciate you getting back to me. Have a good weekend all!
Hi HK, always found your posts interesting and very will informed. Do you have a view on whether more runs will be required and if so how many. Would appreciate comments. Thank you!
You go to a bathroom. You light up a candle. You turn of the lights. You look in the mirror and say Stu five times in the mirror. Then he will appear. Just ask the AVCT guys!
HH - Thought provoking research. Please see below all....
In this presentation, Cawood focused on transient lentiviral manufacturing, plasmid creation and analysis, and stable cell-line development for continuous lentiviral production. The work is performed at WuXi Advanced
Therapies facilities in Philadelphia, PA, based on methods developed at the company’s research institute in Oxford, UK. The latter site was Oxgene, a company that Cawood founded and that was acquired by WuXi Advanced Therapies in 2021.
https://bioprocessintl.com/sponsored-content/improvements-and-innovations-in-lentiviral-manufacture/
Hi Micky, no I’m not concerned Vlad explained two areas on the call, manufacturing and clinical protocol. He went further to explain that the items relating to protocol were suggestions only (I.e non hold issues). He then explained that the only question in relation to the manufacturing related to the purity of one component that was used in the creation of the CAR-T cells. Further to that he stated that they understand the concern and that they are ready to address it. Not worried at all, let’s get the letter in and start moving forward!
Those articles are available on the TMS website and have already been released, suspect the links are just broken